News

AstraZeneca PLC closed 12.32% short of its 52-week high of £133.88, which the company achieved on September 3rd.
The treatment is one for those suffering with lung cancer who never smoked, a group of patients who account for up to 25% of those who develop the disease due to an oncogenic driver mutation. Tagrisso ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
He said about Britain that the firm needed “to see that there is access and a reason to invest.” This is partly a negotiating tactic to get a better deal from the British government, including on what ...
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for AstraZeneca’s ...
While the numbers may seem high, they are still far below the pay of top executives in the United States, the study has found ...
Coffee Day Enterprises reported a consolidated net profit of Rs 28 crore for Q1 FY26. This marks a sharp improvement from the ...